Active substanceHydrochlorothiazide + LysinoprilHydrochlorothiazide + Lysinopril
Similar drugsTo uncover
  • Iruzid®
    pills inwards 
  • Lisinopril ND-KRKA
    pills inwards 
  • Lizinopril NL 20-KRKA
    pills inwards 
  • Lisinopril NL-KRKA
    pills inwards 
  • Listril® Plus
    pills inwards 
  • Liten H
    pills inwards 
    Boznalek, AO     Bosnia and Herzegovina
  • Dosage form: & nbsppills
    Composition:

    tablets 10 + 12.5 mg: one tablet contains active ingredients: lisinopril dihydrate (in terms of lisinopril anhydrous) 10 mg and hydrochlorothiazide 12.5 mg. Excipients: mannitol, calcium phosphate dihydrate, corn starch, pregelatinized starch, indigocarmine, magnesium stearate.

    tablets 20 + 12.5 mg: one tablet contains the active substances: lisinopril dihydrate (in terms of lisinopril anhydrous) 20 mg and hydrochlorothiazide 12.5 mg. Excipients: mannitol, calcium phosphate dihydrate, corn starch, pregelatinized starch, iron oxide oxide yellow, magnesium stearate.

    tablets 20 + 25 mg: one tablet contains active substances: lisinopril dihydrate (in terms of lisinopril anhydrous) 20 mg and hydrochlorothiazide 25 mg.Excipients: mannitol, calcium phosphate dihydrate, corn starch, pregelatinized starch, iron oxide red oxide, magnesium stearate.

    Description:

    tablets 10 + 12.5 mg: blue, biconvex, hexagonal tablets,

    tablets 20 + 12.5 mg: yellow, biconvex, hexagonal tablets,

    tablets 20 + 25 mg: light pink, biconcave, round tablets.

    Pharmacotherapeutic group:Hypotensive combined agent (angiotensin-converting enzyme inhibitor + diuretic)
    ATX: & nbsp

    C.09.B.A.03   Lizinopril in combination with diuretics

    Pharmacodynamics:

    Hypotensive combination. Has antihypertensive and diuretic effect.

    Lisinopril

    The ACE inhibitor reduces the formation of angiotensin II from angiotensin I. Reducing angiotensin II leads to a direct decrease in the release of aldosterone. Reduces the degradation of bradykinin and increases the synthesis of prostaglandins. Reduces the overall peripheral vascular resistance, arterial pressure (BP), preload, pressure in the pulmonary capillaries, causes an increase in the minute volume of blood and increased tolerance to stress in patients with chronic heart failure. Expands arteries more than veins.Some effects are explained by the effect on tissue renin-angiotensin systems. With prolonged use, the severity of myocardial hypertrophy and the walls of arteries of resistive type decreases. Improves the blood supply of the ischemic myocardium. ACE inhibitors prolong life expectancy in patients with chronic heart failure, slow the progression of left ventricular dysfunction in patients who underwent myocardial infarction without clinical manifestations of heart failure. The antihypertensive effect begins in about 6 hours and persists for 24 hours. The duration of the effect also depends on the size of the dose. The action takes about 1 hour. The maximum effect is determined in 6-7 hours. With arterial hypertension, the effect is observed in the first days after the start of treatment, stable action develops after 1-2 months.

    With a sharp withdrawal of the drug, there is no pronounced increase in blood pressure.

    In addition to lowering blood pressure lisinopril reduces albuminuria. In patients with hyperglycemia contributes to the normalization of the function of the damaged glomerular endothelium.

    Lizinopril does not affect the concentration of glucose in the blood in patients with diabetes mellitus and does not increase the incidence of hypoglycemia.

    Hydrochlorothiazide

    A thiazide diuretic whose diuretic effect is associated with a disruption of the reabsorption of sodium, chlorine, potassium, magnesium, water in the distal nephron; delays the excretion of calcium ions, uric acid. Has antihypertensive properties; the hypotensive effect develops due to the expansion of arterioles. Virtually no effect on normal blood pressure. Diuretic effect occurs in 1-2 hours, reaches a maximum after 4 hours and lasts 6-12 hours. Antihypertensive effect occurs in 3-4 days, but it may take 3-4 weeks to achieve the optimal therapeutic effect.

    Lysinopril and hydrochlorothiazide, if applied simultaneously, have an additive antihypertensive effect.

    Indications:Arterial hypertension (in patients who are shown combined therapy).
    Contraindications:Hypersensitivity to the drug, other ACE inhibitors and sulfanylamide derivatives, anuria,expressed renal insufficiency (creatinine clearance less than 30 ml / min), angioedema (including in history from the use of ACE inhibitors), hemodialysis using high-flow membranes, hypercalcemia, hyponatremia, porphyria, precoma, hepatic coma, severe diabetes mellitus , age to 18 years (efficacy and safety not established).
    Carefully:Aortic stenosis / hypertrophic cardiomyopathy, bilateral stenosis of the renal arteries, stenosis of the artery of a single kidney with progressive azotemia, condition after kidney transplantation, renal failure (creatinine clearance more than 30 ml / min), primary hyperaldosteronism, hypotension, bone marrow hypoplasia, hyponatremia risk of developing arterial hypotension in patients on a low-salt or salt-free diet), hypovolemic conditions (including diarrhea, vomiting), joint disease tion tissue (systemic lupus erythematosus, scleroderma), diabetes, gout, depression of bone marrow hematopoiesis, hyperuricemia, hyperkalemia, coronary heart disease,cerebrovascular diseases (including cerebral circulatory insufficiency), severe chronic heart failure, hepatic impairment, and advanced age.
    Pregnancy and lactation:
    The use of lisinopril during pregnancy is contraindicated. When establishing a pregnancy, the drug should be stopped as soon as possible. The intake of inhibitors in the II and III trimester of pregnancy has an adverse effect on the fetus (there may be a marked decrease in blood pressure, renal failure, hyperkalemia, skull hypoplasia, fetal death). Data on the negative effects of the drug on the fetus in case of application during the I trimester are not present. For newborns and infants who have undergone intrauterine exposure to ACE inhibitors, it is recommended to monitor for the timely detection of a marked decrease in blood pressure, oliguria, and hyperkalemia.
    For the period of treatment the drug should be abolished breastfeeding.
    Dosing and Administration:

    Inside.

    For 1 tablet of Heruzida ® 10 mg + 12.5 mg or 20 mg + 12.5 mg once a day.Sometimes, if necessary, the dose can be increased to Iruzide® 20 mg + 25 mg once daily.

    Dose for renal failure:

    In patients with creatinine clearance from 30 and less than 80 ml / min, the drug can be used only after adjusting the dose of individual components of the drug. The recommended initial dose of lisinopril in uncomplicated renal failure is 5-10 mg.

    Prior therapy with diuretics:

    Symptomatic hypotension can occur after taking the initial dose of the drug. Such cases are more common in patients who have had a loss of fluid and electrolytes due to previous treatment with diuretics. Therefore, you should stop taking diuretics 2-3 days before starting treatment with the drug (see SPECIAL INSTRUCTIONS).

    Side effects:

    The most common side effects: dizziness, headache. Other side effects:

    From the cardiovascular system: marked decrease in blood pressure, chest pain, rarely - orthostatic hypotension, tachycardia, bradycardia, the appearance of symptoms of heart failure, violation of atrioventricular conduction, myocardial infarction.

    From the digestive tract: nausea, vomiting, abdominal pain, dry mouth, diarrhea, dyspepsia, anorexia, taste change, pancreatitis, hepatitis (hepatocellular and cholestatic), jaundice.

    From the skin: urticaria, increased sweating, photosensitivity, skin itching, hair loss.

    From the nervous system: lability of mood, violation of concentration, paresthesia, fatigue, drowsiness, convulsive twitching of the muscles of the limbs and lips, rarely - asthenic syndrome, confusion.

    From the respiratory system: dyspnea, bronchospasm, apnea.

    On the part of the hematopoiesis system: leukopenia, thrombocytopenia, neutropenia, agranulocytosis, anemia (decrease in hemoglobin, hematocrit, erythrocytopenia).

    Allergic reactions: angioedema, facial edema, extremities, lips, tongue, epiglottis and / or larynx (see SPECIAL INSTRUCTIONS), skin rashes, itching, fever, vasculitis, positive responses to antinuclear antibodies, increased ESR, eosinophilia.

    From the genitourinary system: uremia, oliguria / anuria, impaired renal function, acute renal failure, decreased potency.

    Laboratory indicators: hyperkalemia and / or hypokalemia, hyponatremia, hypomagnesemia, hypochloraemia, hypercalcemia, hyperuricemia, hyperglycemia, elevated levels of urea and creatinine in blood plasma, hyperbilirubinemia, hypercholesterolemia, hypertriglyceridemia, decreased glucose tolerance, increased activity of "liver" transaminases, especially in the presence of an anamnesis kidney disease, diabetes mellitus, and renovascular hypertension.

    Other: dry cough, arthralgia, arthritis, myalgia, fever, impaired fetal development, exacerbation of gout.

    Overdose:

    Symptoms: A marked decrease in blood pressure, dry mouth, drowsiness, urinary retention, constipation, anxiety, increased irritability.

    Treatment: symptomatic therapy, intravenous fluid administration, blood pressure control, therapy aimed at correction of dehydration and water-salt balance disorders. Control of urea, creatinine and electrolytes in blood serum, as well as diuresis.

    Interaction:

    When used simultaneously with potassium-sparing diuretics (spironolactone, triamterene, amiloride), potassium preparations, salt substitutes, containing potassium-a risk of hyperkalemia is increased, especially in patients with impaired renal function. Therefore, they can be jointly administered only on the basis of an individual decision of the treating physician with regular monitoring of potassium level in the serum and kidney function. With simultaneous use with vasodilators, barbiturates, phenothiazines, tricyclic antidepressants, ethanol - strengthening of the hypotensive effect. When used simultaneously with non-steroidal anti-inflammatory drugs (indomethacin and others), estrogen - a decrease in the antihypertensive effect of lisinopril. With simultaneous use with lithium preparations - slowing the excretion of lithium from the body (increased cardiotoxic and neurotoxic action of lithium). With simultaneous use with antacids and colestyramine - reduced absorption in the gastrointestinal tract.

    The drug enhances the neurotoxicity of salicylates, weakens the effect of oral hypoglucemic drugs, norepinephrine, epinephrine and antidotal drugs, increases the effects (including side effects) of cardiac glycosides, the action of peripheral muscle relaxants, reduces the excretion of quinidine.

    Reduces the effect of oral contraceptives. Ethanol strengthens the hypotensive effect of the drug. With the simultaneous administration of methyldopa, the risk of hemolysis increases.

    Special instructions:

    Symptomatic hypotension

    Most often, a marked decrease in blood pressure occurs when the volume of fluid caused by diuretic therapy decreases, the amount of salt in the diet decreases, dialysis, diarrhea, or vomiting (see INTERACTION WITH OTHER MEDICINES and ADVERSE EFFECTS). In patients with chronic heart failure with simultaneous renal failure or without it, a marked decrease in blood pressure is possible. It is more often detected in patients with a severe degree of heart failure, as a result of the use of large doses of diuretics, hyponatremia or impaired renal function. In such patients, treatment should begin under the strict supervision of a physician. Similar rules should be adhered to when assigning patients with coronary heart disease, cerebrovascular insufficiency, in which a sharp decrease in blood pressure can lead to myocardial infarction or stroke.

    Transient hypotensive reaction is not a contraindication for taking the next dose of the drug.

    Before the start of treatment, if possible, the sodium concentration should be normalized and / or replace the lost volume of fluid, carefully monitor the effect of the initial dose of the drug on the patient.

    Impaired renal function

    In patients with chronic heart failure, a marked decrease in blood pressure after initiation of treatment with ACE inhibitors may lead to further deterioration of renal function. Cases of acute renal failure are noted. In patients with bilateral renal artery stenosis or stenosis of the single-kidney artery receiving ACE inhibitors, there was an increase in urea and serum creatinine, usually reversible after discontinuation of treatment. It was more common in patients with renal insufficiency.

    Hypersensitivity / Angioedema

    Angioedema of the face, extremities, lips, tongue, epiglottis and / or larynx was rarely seen in patients treated with an ACE inhibitor, including lisinopril, which can occur in any period of treatment.In this case, treatment with lisinopril should be stopped as soon as possible and for the patient to establish an observation until the symptoms regress completely. In cases where the edema appeared only on the face and lips, the condition usually passes without treatment, however, it is possible to prescribe antihistamines. Angioedema with edema of the larynx can be fatal. When the tongue, epiglottis or larynx are covered, airway obstruction can occur, therefore, appropriate therapy should be performed immediately (0.3-0.5 ml epinephrine (adrenaline) 1: 1000 sc) and / or measures to ensure airway patency.

    Patients who have had a history of angioedema, not associated with previous treatment with ACE inhibitors, may have an increased risk of developing it during treatment with an ACE inhibitor.

    Cough

    When an ACE inhibitor was used, a cough was noted. Cough is dry, prolonged, which disappears after discontinuing treatment with an ACE inhibitor. With a differential diagnosis of cough, one must also consider a cough caused by the use of an ACE inhibitor.

    Patients on hemodialysis

    Anaphylactic reaction was noted in patients undergoing hemodialysis using dialysis membranes with high permeability, which simultaneously take ACE inhibitors. In such cases, one should consider the possibility of using another type of membrane for dialysis or another antihypertensive drug.

    Surgery / General Anesthesia

    When using drugs that reduce blood pressure in patients with extensive surgery or during general anesthesia lisinopril can block the formation of angiotensin II.

    The pronounced decrease in blood pressure, which is considered a consequence of this mechanism, can be eliminated by increasing the volume of circulating blood.

    Before surgery (including dentistry), it is necessary to alert the surgeon / anesthesiologist about the use of ACE inhibitors.

    Potassium in the serum

    In some cases, hyperkalemia was noted.

    Risk factors for the development of hyperkalemia include renal failure, diabetes mellitus, the use of potassium drugs or drugs that cause an increase in the potassium concentration in the blood (eg, heparin), especially in patients with impaired renal function.In patients who have a risk of symptomatic hypotension (on a low-salt or salt-free diet) with or without hyponatremia, as well as in patients who received high doses of diuretics, the above conditions must be compensated before the start of treatment (loss of fluid and salts). Metabolic and endocrine effects

    Thiazide diuretics can influence glucose tolerance, so dosage of antidiabetic drugs should be adjusted.

    Thiazide diuretics can reduce the secretion of calcium in the urine and cause hypercalcemia. Expressed hypercalcemia may be a symptom of latent hyperparathyroidism. It is recommended to stop treatment with thiazide diuretics before the parathyroid gland function test.

    During the treatment with the drug, regular monitoring of the blood plasma of potassium, glucose, urea, fats and lipids is necessary.

    During the period of treatment it is not recommended to drink alcoholic beverages, since alcohol enhances the hypotensive effect of the drug.

    Care should be taken when performing physical exercises,hot weather (the risk of dehydration and excessive decrease in blood pressure due to a decrease in the volume of circulating blood).

    Effect on the ability to drive transp. cf. and fur:During the treatment period, one should refrain from driving motor vehicles and practicing potentially dangerous activities that require an increased concentration of attention and speed of psychomotor reactions, since dizziness is possible, especially at the beginning of the course of treatment.
    Form release / dosage:
    Tablets 10 + 12.5 mg, 20 + 12.5 mg, 20 + 25 mg.
    Packaging:

    For 30 tablets in PVC / PVDC-Al blister.

    One blister is placed together with instructions for use in a cardboard box.

    Storage conditions:
    List B. At a temperature not higher than 25 C. Keep out of the reach of children!
    Shelf life:
    3 years. Do not use after the expiration date printed on the package.
    Terms of leave from pharmacies:On prescription
    Registration number:LSR-002308/07
    Date of registration:17.08.2007
    Expiration Date:Unlimited
    The owner of the registration certificate:Beluga, medicines and cosmetics.Beluga, medicines and cosmetics. Croatia
    Manufacturer: & nbsp
    Representation: & nbspBeluga, medicines and cosmetics. Beluga, medicines and cosmetics. Croatia
    Information update date: & nbsp28.11.2017
    Illustrated instructions
      Instructions
      Up